Novo Nordisk Expands Legal Action Against Unapproved Weight-Loss Drugs

Novo Nordisk's Legal Strategy

• ⚖️ Novo Nordisk is expanding its legal action to protect patients from non-FDA approved weight-loss drugs.
• 🎯 The company is specifically targeting the use of unapproved semaglutide, the main ingredient in Ozempic and Wegovy.
• 📈 Novo Nordisk has filed 14 new lawsuits, bringing their total to 132 federal court filings.

Impact on Drug Compounding

• 📉 Novo Nordisk previously lowered its full-year guidance due to the issue of compounded GLP-1 drugs.
• ⚠️ The company expected compounding to cease earlier in the year, but this has not occurred.
• 🔄 CEO Andrew Dutton noted a step-down in results primarily due to customers transitioning to Novo's commercially available GLP-1 drugs.

Broader Pharmaceutical Landscape

• 💊 Analysts do not expect this compounding issue to significantly impact Eli Lilly, as the focus has been on semaglutide.
• 📊 Pfizer reported a broad beat on earnings, with strength in heart and blood-thinning drugs, and a surprising COVID-19 beat.
• 💰 Pfizer raised its full-year adjusted EPS guidance due to cost-cutting measures and a lower tax rate, but did not raise full-year sales guidance due to conservatism regarding fall COVID sales.

Drug Pricing and Tariffs

• 🗣️ President Trump sent letters to 17 large drug makers asking them to lower US drug prices to align with international levels.
• 💬 Pfizer CEO Albert Bourla stated that discussions with the administration regarding drug pricing are ongoing and productive.
• 📈 Pfizer's earnings report incorporates the impact of tariffs and potentially lower prices due to the President's request.